Main page content

Displaying results 41 - 50 of 176
Publication ID: PEP22-08-03-005
Published:

This 18x24 inch poster helps publicize the new 988 Suicide & Crisis Lifeline and provides access to this life-saving resource. This poster is designed to be placed in community centers, counseling offices, clinics, and other settings where people gather.

Publication ID: PEP22-08-03-008
Published:
Este póster de 18x24 pulgadas ayuda a publicitar el nuevo 988 Línea de Prevención del Suicido y Crisis y proporciona acceso a este recurso que salva vidas. Este póster está diseñado para ser colocado en escuelas, centros comunitarios, oficinas de asesoramiento, clínicas y otros lugares donde se reúnen las personas.
Publication ID: PEP22-08-03-002
Published:

This 2-sided 3.5"x2" business-sized wallet card helps publicize the 988 Suicide & Crisis Lifeline.

Publication ID: PEP22-07-03-001
Published:

An analysis of 2021 preliminary data presents (1) nationally representative weighted estimates for the top five drugs in drug-related ED visits, (2) the assessment of monthly trends and drugs involved in polysubstance ED visits in a subset of sentinel hospitals, and (3) the identification of drugs new to DAWN’s Drug Reference Vocabulary.

Publication ID: PEP21-05-00-002
Published:

There are protections in federal law, collectively known as “parity,” which are designed to ensure that certain types of health plans cover mental and substance use disorders no less generously than they cover other health issues. This resource can guide you to helpful materials and places.

Publication ID: PEP21-05-00-001
Published:

This document provides an overview of essential information necessary for understanding mental health and substance use disorder parity and how to implement and comply with federal parity laws. This guide applies to parity laws in employer-sponsored health plans and group and individual insurance.

Publication ID: PEP21-05-00-003
Published:

This brochure gives an overview of the Mental Health Parity and Addiction Equity Act of 2008. It lists some of the common limits placed on mental health and substance use disorder benefits and services.

Publication ID: PEP21-06-01-002
Published:

This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.

Publication ID: PEP21-06-01-003
Published:

This Advisory reviews the evidence on prescription stimulant misuse among youth and young adults. It establishes prescription stimulant misuse as a public health problem, identifies associated risk and protective factors, and provides programs and action steps for stakeholders to prevent misuse.

Publication ID: PEP21-02-01-004
Published:

This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.

Displaying 41 - 50 out of 176